PMID- 21076523
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20220316
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2010
DP  - 2010
TI  - Dendritic cell-based immunotherapy for prostate cancer.
PG  - 517493
LID - 10.1155/2010/517493 [doi]
LID - 517493
AB  - Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which 
      display an extraordinary capacity to induce, sustain, and regulate T-cell 
      responses providing the opportunity of DC-based cancer vaccination strategies. 
      Thus, clinical trials enrolling prostate cancer patients were conducted, which 
      were based on the administration of DCs loaded with tumor-associated antigens. 
      These clinical trials revealed that DC-based immunotherapeutic strategies 
      represent safe and feasible concepts for the induction of immunological and 
      clinical responses in prostate cancer patients. In this context, the 
      administration of the vaccine sipuleucel-T consisting of autologous peripheral 
      blood mononuclear cells including APCs, which were pre-exposed in vitro to the 
      fusion protein PA2024, resulted in a prolonged overall survival among patients 
      with metastatic castration-resistant prostate cancer. In April 2010, sipuleucel-T 
      was approved by the United States Food and Drug Administration for prostate 
      cancer therapy.
FAU - Jahnisch, Hanka
AU  - Jahnisch H
AD  - Institute of Immunology, Medical Faculty, Technical University of Dresden, 
      Fetscherstrasse 74, Dresden, Germany.
FAU - Fussel, Susanne
AU  - Fussel S
FAU - Kiessling, Andrea
AU  - Kiessling A
FAU - Wehner, Rebekka
AU  - Wehner R
FAU - Zastrow, Stefan
AU  - Zastrow S
FAU - Bachmann, Michael
AU  - Bachmann M
FAU - Rieber, Ernst Peter
AU  - Rieber EP
FAU - Wirth, Manfred P
AU  - Wirth MP
FAU - Schmitz, Marc
AU  - Schmitz M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101104
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Tissue Extracts)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 8Q622VDR18 (sipuleucel-T)
RN  - EC 3.1.3.2 (Acid Phosphatase)
RN  - EC 3.1.3.2 (PA2024 fusion protein, human)
SB  - IM
MH  - Acid Phosphatase/immunology/metabolism
MH  - Animals
MH  - Antigen-Presenting Cells/immunology
MH  - Antigens, Neoplasm/immunology/metabolism
MH  - *Cancer Vaccines
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology
MH  - Drug Approval
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/immunology/metabolism
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Lymphocyte Activation
MH  - Male
MH  - Prostatic Neoplasms/*immunology/pathology/*therapy
MH  - Recombinant Fusion Proteins/immunology/metabolism
MH  - Tissue Extracts/*therapeutic use
MH  - United States
PMC - PMC2975068
EDAT- 2010/11/16 06:00
MHDA- 2011/06/15 06:00
PMCR- 2010/11/04
CRDT- 2010/11/16 06:00
PHST- 2010/06/30 00:00 [received]
PHST- 2010/10/07 00:00 [accepted]
PHST- 2010/11/16 06:00 [entrez]
PHST- 2010/11/16 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
PHST- 2010/11/04 00:00 [pmc-release]
AID - 10.1155/2010/517493 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4.